Obesity and ckd progression: Hard facts on fat ckd patients

Nephrology Dialysis Transplantation

Volumn 28, Issue SUPPL.4, 2013, Pages

  Mallamaci, Francesca ^a   Tripepi, Giovanni ^a  

^a CNR   (Italy)

Author keywords

Body mass index; Chronic kidney disease; Obesity

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; PROCALCITONIN; RAMIPRIL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ALDOSTERONE RELEASE; BARIATRIC SURGERY; BLOOD PRESSURE REGULATION; BODY MASS; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; HUMAN; HYPERALDOSTERONISM; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; META ANALYSIS (TOPIC); MORBID OBESITY; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; VASODILATATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION;

BODY MASS INDEX; CHRONIC KIDNEY DISEASE; OBESITY;

ADIPOSITY; DISEASE PROGRESSION; HUMANS; OBESITY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84890076166     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft391     Document Type: Review

References (27)

1. Kosti RI, Panagiotakos DB. The epidemic of obesity in children and adolescents in the world. Cent Eur J Public Health 2006; 14: 151-159
2. Kramer HJ, Saranathan A, Luke A et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453-1459
3. Hsu CY, McCulloch CE, Iribarren C et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-28
4. Brown RN, Mohsen A, Green D et al. Body mass index has no effect on rate of progression of chronic kidney disease in non-diabetic subjects. Nephrol Dial Transplant 2012; 27: 2776-2780
5. Yusuf S, Hawken S, Ounpuu S et al. INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649
6. Kramer H, Shoham D, McClure LA et al. Association of waist circumference and body mass index with all-cause mortality in CKD: the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis 2011; 58: 177-185
7. Postorino M, Marino C, Tripepi G, Zoccali C; CREDIT (Calabria Registry of Dialysis and Transplantation) Working Group. Abdominal obesity and all-cause and cardiovascular mortality in endstage renal disease. J Am Coll Cardiol 2009; 53: 1265-1272
8. Elsayed EF, Tighiouart H, Weiner DE et al. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis 2008; 52: 49-57
9. Foster MC, Hwang S-J, Larson MG. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52: 39-48
10. Bonnet F, Deprele C, Sassolas A et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in IgA nephritis. Am J Kidney Dis 2001; 37: 720-727
11. Eknoyan G. Obesity and chronic kidney disease. Nefrologia 2011; 31: 397-403
12. Mallamaci F, Ruggenenti P, Perna A et al. REIN Study Group. ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol 2011; 22: 1122-1128
13. Bosma RJ, van der Heide JJ, Oosterop EJ et al. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int 2004; 65: 259-265
14. Douglas JG, Agodoa L. ACE Inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int Suppl 2003; 83: S74-S76
15. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776-783
16. Ehrhart-Bornstein M, Arakelyan K, Krug AWet al. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 2004; 30: 865-870
17. Rondinone CM, Rodbard D, Baker ME. Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 1993; 132: 2421-2426
18. Guo C, Ricchiuti V, Lian BQ et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-2261
19. Tuck ML, Sowers J, Dornfeld L et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933
20. Dall'Asta C, Vedani P, Manunta P et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis 2009; 19: 110-114
21. Spoto B, Zoccali C. Spleen IL-10, a key player in obesity-driven renal risk. Nephrol Dial Transplant 2013; 28: 1061-1064
22. Xu ZG, Lanting L, Vaziri ND et al. Upregulation of angiotensin 2 type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese zucker rat kidney: reversal by angiotensin 2 type 1 receptor blockade. Circulation 2005; 19: 1962-1969
23. Ma LJ, Corsa BA, Zhou J et al. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol 2011; 300: F1203-F1213
24. Mallamaci F et al. Innate immunity and CKD progression. In: 50th ERA-EDTA Congress, Istanbul, 17-21 May 2013 (Abstract)
25. Navaneethan SD, Yehnert H, Moustarah F et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 10: 1565-1574
26. Navarro-Díaz M, Serra A, Romero R et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 2006; 17(12 Suppl 3): S213-S217
27. Serpa Neto A, Bianco Rossi FM, Dal Moro Amarante R et al. Effect of weight loss after Roux-en-Y gastric bypass, on renal function and blood pressure in morbidly obese patients. J Nephrol 2009; 22: 637-646